Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2022

04-01-2022 | Endoscopy | Original Article

Ethnicity Is an Important Consideration in Screening for Gastric Intestinal Metaplasia

Authors: Eugene Kligman, Hiba Ali, Ellie Chen, Frederick Peng, David Szafron, Kristen Staggers, Mimi C. Tan, Kalpesh Patel, Mohamed O. Othman

Published in: Digestive Diseases and Sciences | Issue 9/2022

Login to get access

Abstract

Background

Gastric intestinal metaplasia (GIM) is a precursor to gastric adenocarcinoma, making it an attractive target for early detection by endoscopy. The aim of this study was to determine the prevalence, risk factors, and associated histologic findings of GIM among patients undergoing endoscopy in a diverse US population.

Methods

We conducted a retrospective, cross-sectional study of patients undergoing elective endoscopy with gastric biopsies at 6 academic and community centers in Houston, Texas. GIM prevalence was estimated with a 95% confidence interval (CI), and patient demographic and clinical characteristics were summarized using mean with standard deviation, or frequency with percentage. Generalized estimating equations (GEE) were used to compare characteristics between those with and without GIM.

Results

Our final cohort consisted of 2685 patients, including 216 cases with GIM and 2469 controls. The prevalence of GIM in our cohort was 8.04% (95% CI 7.07%, 9.14%). The mean age of GIM cases was higher than in the control group (59.8 vs 54.7 years, p < 0.0001). The prevalence of GIM in Asians, Hispanic, Black and Non-Hispanic Whites (NHW) was 14.7%, 11.7%, 9.8% and 5.8%, respectively. On multivariable analysis, factors associated with GIM include age (adj. OR 1.32 per 10 year increase, p < 0.0001), habitual smoking (adj. OR 1.68, p < 0.0001), and race (compared to NHW: Asian, adj. OR 2.34, p = 0.010; Hispanic, adj. OR 2.15, p < 0.001; Black, adj. OR 1.61, p < 0.001).

Conclusion

Asians, Hispanics, and African Americans have higher rates of GIM than NHW. Ethnicity should be an important consideration on determining who to screen for GIM in the US.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.CrossRef Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.CrossRef
2.
go back to reference Jencks DS, Adam JD, Borum ML et al. Overview of current concepts in gastric intestinal metaplasia and gastric cancer. Gastroenterol Hepatol (NY) 2018;14:92–101. Jencks DS, Adam JD, Borum ML et al. Overview of current concepts in gastric intestinal metaplasia and gastric cancer. Gastroenterol Hepatol (NY) 2018;14:92–101.
3.
go back to reference Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019;14:26–38.PubMed Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019;14:26–38.PubMed
4.
go back to reference Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol 2020;18:534–542.CrossRef Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol 2020;18:534–542.CrossRef
5.
go back to reference Correa P. Gastric cancer: overview. Gastroenterol Clin N Am 2013;42:211–217.CrossRef Correa P. Gastric cancer: overview. Gastroenterol Clin N Am 2013;42:211–217.CrossRef
6.
go back to reference Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015;20:25–40.CrossRef Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015;20:25–40.CrossRef
7.
go back to reference de Vries AC, van Grieken NC, Looman CW et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945–952.CrossRef de Vries AC, van Grieken NC, Looman CW et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945–952.CrossRef
8.
go back to reference Li D, Bautista MC, Jiang SF et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol 2016;111:1104–1113.CrossRef Li D, Bautista MC, Jiang SF et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol 2016;111:1104–1113.CrossRef
9.
go back to reference Shaheen NJ, Falk GW, Iyer PG et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016;111:30–50.CrossRef Shaheen NJ, Falk GW, Iyer PG et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016;111:30–50.CrossRef
10.
go back to reference Zhang X, Li M, Chen S et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology 2018;155:347-354.e9.CrossRef Zhang X, Li M, Chen S et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology 2018;155:347-354.e9.CrossRef
11.
go back to reference Gupta S, Li D, El Serag HB et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 2020;158:693–702.CrossRef Gupta S, Li D, El Serag HB et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 2020;158:693–702.CrossRef
12.
go back to reference Haastrup PF, Jarbol DE, Thompson W et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563.CrossRef Haastrup PF, Jarbol DE, Thompson W et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563.CrossRef
13.
go back to reference Sonnenberg A, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 2010;139:1894-1901.e2.CrossRef Sonnenberg A, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 2010;139:1894-1901.e2.CrossRef
14.
go back to reference Almouradi T, Hiatt T, Attar B. Gastric intestinal metaplasia in an underserved population in the USA: prevalence, epidemiologic and clinical features. Gastroenterol Res Pract 2013;2013:856256.CrossRef Almouradi T, Hiatt T, Attar B. Gastric intestinal metaplasia in an underserved population in the USA: prevalence, epidemiologic and clinical features. Gastroenterol Res Pract 2013;2013:856256.CrossRef
15.
go back to reference Tan MC, Mallepally N, Liu Y et al. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol 2020;115:381–387.CrossRef Tan MC, Mallepally N, Liu Y et al. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol 2020;115:381–387.CrossRef
16.
go back to reference Choi AY, Strate LL, Fix MC et al. Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a US population. Gastrointest Endosc 2018;87:1023–1028.CrossRef Choi AY, Strate LL, Fix MC et al. Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a US population. Gastrointest Endosc 2018;87:1023–1028.CrossRef
17.
go back to reference Kim N, Park YS, Cho SI et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008;13:245–255.CrossRef Kim N, Park YS, Cho SI et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008;13:245–255.CrossRef
18.
go back to reference Lee TY, Wang RC, Lee YC et al. The incidence of gastric adenocarcinoma among patients with gastric intestinal metaplasia: a long-term cohort study. J Clin Gastroenterol 2016;50:532–537.CrossRef Lee TY, Wang RC, Lee YC et al. The incidence of gastric adenocarcinoma among patients with gastric intestinal metaplasia: a long-term cohort study. J Clin Gastroenterol 2016;50:532–537.CrossRef
19.
go back to reference Huang JQ, Sridhar S, Chen Y et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169–1179.CrossRef Huang JQ, Sridhar S, Chen Y et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169–1179.CrossRef
20.
go back to reference Leung WK, Lin SR, Ching JY et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244–1249.CrossRef Leung WK, Lin SR, Ching JY et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244–1249.CrossRef
21.
go back to reference Sung JJ, Lin SR, Ching JY et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7–14.CrossRef Sung JJ, Lin SR, Ching JY et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7–14.CrossRef
22.
go back to reference Chen HN, Wang Z, Li X et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016;19:166–175.CrossRef Chen HN, Wang Z, Li X et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016;19:166–175.CrossRef
23.
go back to reference Kneller RW, You WC, Chang YS et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992;84:1261–1266.CrossRef Kneller RW, You WC, Chang YS et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992;84:1261–1266.CrossRef
25.
go back to reference Morais S, Rodrigues S, Amorim L et al. Tobacco smoking and intestinal metaplasia: systematic review and meta-analysis. Dig Liver Dis 2014;46:1031–1037.CrossRef Morais S, Rodrigues S, Amorim L et al. Tobacco smoking and intestinal metaplasia: systematic review and meta-analysis. Dig Liver Dis 2014;46:1031–1037.CrossRef
26.
go back to reference Pittayanon R, Rerknimitr R, Klaikaew N et al. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. Aliment Pharmacol Ther 2017;46:40–45.CrossRef Pittayanon R, Rerknimitr R, Klaikaew N et al. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. Aliment Pharmacol Ther 2017;46:40–45.CrossRef
27.
go back to reference Lundell L, Miettinen P, Myrvold HE et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999;117:319–326.CrossRef Lundell L, Miettinen P, Myrvold HE et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999;117:319–326.CrossRef
28.
go back to reference Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev 2014;2014:CD010623. Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev 2014;2014:CD010623.
29.
go back to reference Saumoy M, Schneider Y, Shen N et al. Cost effectiveness of gastric cancer screening according to race and ethnicity. Gastroenterology 2018;155:648–660.CrossRef Saumoy M, Schneider Y, Shen N et al. Cost effectiveness of gastric cancer screening according to race and ethnicity. Gastroenterology 2018;155:648–660.CrossRef
30.
go back to reference Kim SG, Park CM, Lee NR et al. Long-term clinical outcomes of endoscopic submucosal dissection in patients with early gastric cancer: a prospective multicenter cohort study. Gut Liver 2018;12:402–410.CrossRef Kim SG, Park CM, Lee NR et al. Long-term clinical outcomes of endoscopic submucosal dissection in patients with early gastric cancer: a prospective multicenter cohort study. Gut Liver 2018;12:402–410.CrossRef
Metadata
Title
Ethnicity Is an Important Consideration in Screening for Gastric Intestinal Metaplasia
Authors
Eugene Kligman
Hiba Ali
Ellie Chen
Frederick Peng
David Szafron
Kristen Staggers
Mimi C. Tan
Kalpesh Patel
Mohamed O. Othman
Publication date
04-01-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07326-2

Other articles of this Issue 9/2022

Digestive Diseases and Sciences 9/2022 Go to the issue